Leflunomide

Results: 160



#Item
81PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a

PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2014-05-29 15:15:36
82HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTEZLA safely and effectively. See full prescribing information for OTEZLA. OTEZLA® (apremilast) tablets, for oral

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTEZLA safely and effectively. See full prescribing information for OTEZLA. OTEZLA® (apremilast) tablets, for oral

Add to Reading List

Source URL: www.otezla.com

Language: English - Date: 2014-07-28 16:03:46
83Xeljanz® (tofacitinib tablets – Pfizer) To Initiate a Coverage Review, Call[removed]OVERVIEW Xeljanz is an inhibitor of the Janus kinases (JAK) pathways approved for the treatment of adults with moderately to s

Xeljanz® (tofacitinib tablets – Pfizer) To Initiate a Coverage Review, Call[removed]OVERVIEW Xeljanz is an inhibitor of the Janus kinases (JAK) pathways approved for the treatment of adults with moderately to s

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2014-08-12 13:02:45
84Division of Pediatric Drug Development

Division of Pediatric Drug Development

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2005-07-07 15:31:06
85Attention-deficit hyperactivity disorder / Stimulants / Nootropics / Childhood psychiatric disorders / Sleep disorders / Methylphenidate / Attention deficit hyperactivity disorder / Leflunomide / Modafinil / Medicine / Chemistry / Organic chemistry

Client Contract Number – Client Name – MA-PD/PDP Prior Authorization Criteria and Guidelines Acne 5

Add to Reading List

Source URL: www.mainecarepdl.org

Language: English - Date: 2012-04-02 13:55:27
86Summary of AHRQ’s Comparative Effectiveness Review of Drug Therapy for Rheumatoid Arthritis (RA) in Adults – An Update Jasvinder A. Singh, MD, MPH Davecia R. Cameron, MS

Summary of AHRQ’s Comparative Effectiveness Review of Drug Therapy for Rheumatoid Arthritis (RA) in Adults – An Update Jasvinder A. Singh, MD, MPH Davecia R. Cameron, MS

Add to Reading List

Source URL: ce.effectivehealthcare.ahrq.gov

Language: English - Date: 2012-05-31 09:51:18
87NEW EXCEPTION DRUG STATUS LISTINGS:

NEW EXCEPTION DRUG STATUS LISTINGS:

Add to Reading List

Source URL: formulary.drugplan.health.gov.sk.ca

Language: English - Date: 2014-06-26 15:57:54
88#84  August, 2000 QUARTERLY UPDATE TO THE 50th EDITION

#84 August, 2000 QUARTERLY UPDATE TO THE 50th EDITION

Add to Reading List

Source URL: formulary.drugplan.health.gov.sk.ca

Language: English - Date: 2014-06-26 15:57:56
89The New Brunswick Drug Plans Special Authorization Criteria ABATACEPT (ORENCIA) 250mg vial for intravenous injection  • For the treatment of Juvenile Rheumatoid Arthritis:

The New Brunswick Drug Plans Special Authorization Criteria ABATACEPT (ORENCIA) 250mg vial for intravenous injection • For the treatment of Juvenile Rheumatoid Arthritis:

Add to Reading List

Source URL: www.gnb.ca

Language: English - Date: 2014-09-05 11:31:26
90NEW EXCEPTION DRUG STATUS LISTINGS:

NEW EXCEPTION DRUG STATUS LISTINGS:

Add to Reading List

Source URL: formulary.drugplan.health.gov.sk.ca

Language: English - Date: 2014-06-26 15:57:57